Stockreport

CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Associat...

CohBar, Inc.  (CWBR) 
NASDAQ:AMEX Investor Relations: ir.cohbar.com
PDF MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company focused on developing mitochondria based ther [Read more]